Bezafibrate

A lipid-lowering medication

Bezafibrate
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Bezafibrate is a fibrate medication used to treat hyperlipidemia, a condition characterized by elevated levels of lipids in the blood. It is primarily used to lower cholesterol and triglyceride levels, thereby reducing the risk of cardiovascular disease.

Mechanism of Action

Bezafibrate works by activating peroxisome proliferator-activated receptors (PPARs), which are nuclear receptors that regulate the expression of genes involved in lipid metabolism. By activating PPARs, bezafibrate increases the oxidation of fatty acids and enhances the clearance of triglycerides from the bloodstream. This leads to a reduction in very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) levels, while increasing high-density lipoprotein (HDL) levels.

Clinical Uses

Bezafibrate is indicated for the treatment of various forms of hyperlipidemia, including:

• Hypercholesterolemia
• Hypertriglyceridemia
• Mixed hyperlipidemia

It is often prescribed when dietary measures and other non-pharmacological interventions have failed to adequately control lipid levels.

Side Effects

Common side effects of bezafibrate include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Other potential side effects include:

• Myopathy
• Liver enzyme abnormalities
• Gallstones

Patients are advised to report any unexplained muscle pain or weakness, as this could indicate a serious condition known as rhabdomyolysis.

Contraindications

Bezafibrate is contraindicated in patients with:

• Severe liver disease
• Severe renal impairment
• Pre-existing gallbladder disease

Drug Interactions

Bezafibrate may interact with other medications, including:

• Statins: Increased risk of myopathy and rhabdomyolysis
• Anticoagulants: Enhanced anticoagulant effect

Synthesis

Synthesis of bezafibrate

The synthesis of bezafibrate involves the reaction of 4-chlorobenzoyl chloride with 2-(4-hydroxyphenyl)ethylamine to form an amide intermediate. This intermediate is then reacted with 2-bromo-2-methylpropanoic acid to yield bezafibrate.

Related Pages

• Fibrate
• Hyperlipidemia
• Cholesterol
• Triglyceride